Holen Sie sich die Stockscreener-App
1.21
5.47%
-0.07
Handel nachbörslich:
1.19
-0.02
-1.65%
Schlusskurs vom Vortag:
$1.28
Offen:
$1.27
24-Stunden-Volumen:
137.15K
Relative Volume:
0.05
Marktkapitalisierung:
$2.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.08M
KGV:
-0.1885
EPS:
-6.42
Netto-Cashflow:
$-11.56M
1W Leistung:
-17.69%
1M Leistung:
-42.92%
6M Leistung:
-81.21%
1J Leistung:
-91.52%
1-Tages-Spanne:
$1.11
$1.27
1-Wochen-Bereich:
$1.11
$1.46
52-Wochen-Spanne:
$1.11
$15.45
Enveric Biosciences Inc Stock (ENVB) Company Profile
Firmenname
Enveric Biosciences Inc
Sektor
Branche
Telefon
239-302-1707
Adresse
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
Vergleichen Sie ENVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.21 | 2.27M | 0 | -15.08M | -11.56M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Enveric Biosciences Inc Aktie (ENVB) Neueste Nachrichten
Psychedelic: Enveric, Filament Health report earnings results - TipRanks
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 - BioSpace
Enveric posts $9.5M loss for 2024, but revenue could be on horizon with licensing deals - Green Market Report
Enveric Lands Massive $184M Biotech Licensing Deals as EB-003 Shows Promise - Stock Titan
Enveric Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Enveric Biosciences, Inc. SEC 10-K Report - TradingView
Enveric Biosciences Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Enveric Biosciences Participating in BIO-Europe Spring® - The Bakersfield Californian
Enveric's Game-Changing Approach: Non-Hallucinogenic Mental Health Drugs Take Center Stage at BIO-Europe - Stock Titan
Enveric Biosciences (ENVB) to Release Quarterly Earnings on Monday - Defense World
What is HC Wainwright’s Forecast for ENVB Q4 Earnings? - The AM Reporter
Q4 Earnings Forecast for ENVB Issued By HC Wainwright - Defense World
HC Wainwright Reiterates “Buy” Rating for Enveric Biosciences (NASDAQ:ENVB) - Defense World
Enveric Biosciences, Inc. (ENVB) Seeks Buyers for PsyAI Trademark Amid Shift to Neuroplastogen Development - Insider Monkey
Enveric Biosciences launches RFP solicitation process for PsyAI trademark - Yahoo Finance
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark - 01Net
Enveric Biosciences Says Regains Compliance With Nasdaq Bid Price Rule -March 06, 2025 at 11:30 am EST - Marketscreener.com
Enveric Biosciences Launches Request-For-Proposals Solicitation Process For PsyAI Trademark - Marketscreener.com
Enveric Biosciences regains Nasdaq compliance - Investing.com
Enveric Biosciences to auction PsyAI trademark portfolio - Investing.com
Can Enveric's PsyAI Trademark Sale Capitalize on the $757B AI Healthcare Boom? - StockTitan
Enveric Biosciences regains Nasdaq compliance By Investing.com - Investing.com UK
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions - MSN
Enveric Biosciences stock hits 52-week low at $0.29 - MSN
Enveric Biosciences Discusses Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward in New Video Interview on SNN Network - ACCESS Newswire
Best Small Cap Stocks To Follow NowFebruary 26th - MarketBeat
Top Biotech Stocks To Watch TodayFebruary 26th - MarketBeat
Top Biotech Stocks To Watch Today – February 26th - Defense World
Enveric CEO says company is ‘at the forefront’ of neuroplastogens field - TipRanks
Enveric Biosciences advances novel neuroplastogen EB-003 By Investing.com - Investing.com Canada
Enveric Biosciences CEO Issues Letter to Shareholders - Financial Content
Can Enveric's Non-Hallucinogenic Psychedelic Drug Transform Mental Health Treatment? - Stock Titan
This Biotech Soared On Key Announcement - The Globe and Mail
Biotech Stock Enveric Biosciences (NASDAQ: ENVB) Soars on Patent News - Investorideas.com newswire
Dow Dips Over 100 Points; TJX Earnings Top Views - Benzinga
Stock market news: Enveric Biosciences +105.51%, Porch Group +65.96% among top gainers during midday trading - Business Upturn
Stock market news: AEON Biopharma plummented by 65.33% while Enveric Biosciences skyrocketed by 90.68% during midday trading - Business Upturn
Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum - openPR
Stock market today: Enveric Biosciences +126.69%, AtlasClear Holdings +52.88% among top gainers in early trading - Business Upturn
Stock market today: AEON Biopharma plunged by 63.17% while Enveric Biosciences surged by 124.66% in early trading - Business Upturn
Enveric Biosciences Prepares Presentation for February 2025 - TipRanks
Enveric Biosciences (ENVB) Stock Gains Momentum In Pre-Hour Trading 2 days ago · By Fahim Awan - Stocks Telegraph
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga India
US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&P 500's Four-Day Fall Was A 'Non-Event,' Says Expert - Benzinga
Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds - Microdose Psychedelic Insights
EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD - Benzinga
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent - The Bakersfield Californian
ENVB stock touches 52-week low at $1.47 amid market shifts - Investing.com Nigeria
Psychedelic: Exclusive talk with biotech company Enveric Biosciences - TipRanks
ENVB stock touches 52-week low at $1.47 amid market shifts By Investing.com - Investing.com South Africa
Finanzdaten der Enveric Biosciences Inc-Aktie (ENVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):